Skip to main content

Combination Type 2 Diabetes Pill Gets FDA Nod

January 31, 2012 — The US Food and Drug Administration (FDA) yesterday approved a combination pill containing the dipeptidyl peptidase-4 inhibitor linagliptin and metformin hydrochloride for the treatment of adults with type 2 diabetes.
The linagliptin/metformin combination sold as Jentadueto (Boehringer Ingelheim Pharmaceuticals, Inc, and Eli Lilly & Co) provides a single-tablet option that is taken twice daily. It can be used alone or in combination with a sulfonylurea.
As previously reported by Medscape Medical News, linagliptin (Tradjenta) received FDA approval in May 2011 for improving blood glucose control in adults with type 2 diabetes, either as a stand-alone or in combination with other therapies.
In a 24-week, randomized, double-blind, placebo-controlled study involving 791 adults with type 2 diabetes inadequately managed with diet and exercise, linagliptin plus metformin led to reductions in hemoglobin A1c levels of up to 1.7 percentage points.
A Matter of Convenience
"Most people with type 2 diabetes require more than one medication to help lower their blood sugar, due to the complex nature of type 2 diabetes," Lance Sloan, MD, Texas Institute for Kidney and Endocrine Disorders in Lufkin noted in a statement. "The approval of Jentadueto is exciting because it combines 2 diabetes medications in a single tablet, making it a good option for people who need an additional medication, and for whom both linagliptin and metformin is appropriate."
Anne L. Peters, MD, CDE, director of clinical diabetes programs at the University of Southern California in Beverly Hills, agrees, telling Medscape Medical News that the new linagliptin/metformin combination pill is a matter of "convenience only." Dr. Peters is also a member of Medscape Diabetes & Endocrinology's editorial advisory board.
The linagliptin/metformin combination pill is not indicated for patients with type 1 diabetes or those who have diabetic ketoacidosis. It has not been studied in combination with insulin. The package label contains a boxed warning alerting clinicians that serious adverse effects can occur in patients taking the drug, including lactic acidosis.
The company says the most common adverse effects with linagliptin/metformin are nasopharyngitis and diarrhea. They also note that hypoglycemia was more commonly reported in patients treated with the drug combination and sulfonylurea compared with those treated with the combination of placebo, sulfonylurea, and metformin (22.9% vs 14.8%, respectively). Pancreatitis was reported more often in patients randomly assigned to receive linagliptin (1 per 538 person-years vs 0 in 433 person-years for comparator).

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volume delivered to
Post a Comment
Read more

FDA Approves Tapentadol ER for Diabetic Neuropathy

August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) ( Nucynta , Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time. It is the first opioid to receive this indication, the company notes in a statement today. DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care. Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states. "Although the clinical relevance is unclear," the company n
4 comments
Read more